Evidence map›Paper›PMID 35623028›Full record

ArticleBiomacromolecules2022

Metronidazole Delivery Nanosystem Able To Reduce the Pathogenicity of Bacteria in Colorectal Infection.

Ana Oliveira, Ana Araújo, Luísa C Rodrigues, Catarina S Silva, Rui L Reis, Nuno M Neves, Pedro Leão, Albino Martins

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomacromolecules, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Ana Oliveira3B's Research Group, I3Bs - Research Institute on Biomaterials, Biodegradables & Biomimetics of University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering & Regenerative Medicine, AvePark - Parque de Ciência e Tecnologia, Zona Industrial da Gandra, Barco, Guimarães 4805-017 Portugal.
Ana Araújo3B's Research Group, I3Bs - Research Institute on Biomaterials, Biodegradables & Biomimetics of University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering & Regenerative Medicine, AvePark - Parque de Ciência e Tecnologia, Zona Industrial da Gandra, Barco, Guimarães 4805-017 Portugal.
Luísa C Rodrigues3B's Research Group, I3Bs - Research Institute on Biomaterials, Biodegradables & Biomimetics of University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering & Regenerative Medicine, AvePark - Parque de Ciência e Tecnologia, Zona Industrial da Gandra, Barco, Guimarães 4805-017 Portugal.
Catarina S Silva3B's Research Group, I3Bs - Research Institute on Biomaterials, Biodegradables & Biomimetics of University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering & Regenerative Medicine, AvePark - Parque de Ciência e Tecnologia, Zona Industrial da Gandra, Barco, Guimarães 4805-017 Portugal.
Rui L Reis3B's Research Group, I3Bs - Research Institute on Biomaterials, Biodegradables & Biomimetics of University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering & Regenerative Medicine, AvePark - Parque de Ciência e Tecnologia, Zona Industrial da Gandra, Barco, Guimarães 4805-017 Portugal.
Nuno M Neves3B's Research Group, I3Bs - Research Institute on Biomaterials, Biodegradables & Biomimetics of University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering & Regenerative Medicine, AvePark - Parque de Ciência e Tecnologia, Zona Industrial da Gandra, Barco, Guimarães 4805-017 Portugal.ORCID 0000-0003-3041-0687
Pedro LeãoLife and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus of Gualtar, Braga 4710-057, Portugal.
Albino Martins3B's Research Group, I3Bs - Research Institute on Biomaterials, Biodegradables & Biomimetics of University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering & Regenerative Medicine, AvePark - Parque de Ciência e Tecnologia, Zona Industrial da Gandra, Barco, Guimarães 4805-017 Portugal.ORCID 0000-0003-3868-0251
University of Minho · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metronidazole (MTZ) is a drug potentially used for the treatment of intestinal infections, namely, the ones caused by colorectal surgery. The traditional routes of administration decrease its local effectiveness and present off-site effects. To circumvent such limitations, herein a drug delivery system (DDS) based on MTZ-loaded nanoparticles (NPs) immobilized at the surface of electrospun fibrous meshes is proposed. MTZ at different concentrations (1, 2, 5, and 10 mg mL

Indexed as

ChitosanColorectal NeoplasmsNanoparticlesAnti-Bacterial AgentsBacteriaDrug Delivery SystemsEscherichia coliHumansMetronidazoleVirulenceAnti-Bacterial AgentsChitosanMetronidazole

Identifiers

PMID35623028
PMCPMC9774670
OpenAlexW4281674111

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.